Oral Anticoagulants Preference in Hospitalized Patients with Acute Deep Vein Thrombosis or Non-Valvular Atrial Fibrillation

Ștefan Cristian Vesa 1,†, Sonia Irina Vlaicu 2,†, Sorin Crișan 3,†, Octavia Sabin 1,*#, George Saraci 4,*#, Vitalie Vâcăraș 5, Daciana Elena Popa 6, Paula Pârcaiîb 7, Valer Ioan Donca 8, Antonia Eugenia Macarie 9, Madalina Sava 9 and Anca Dana Buzoianu 4,*

1 Department of Pharmacology, Toxicology and Clinical Pharmacology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania; stefanvesa@gmail.com (S.C.V.); abuzoianu@umfcluj.ro (A.D.B.)
2 Department of Internal Medicine, 1st Medical Clinic, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania; vlaicus@yahoo.com
3 Department of Internal Medicine, 5th Medical Clinic, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400139 Cluj-Napoca, Romania; crisan.sorin@gmail.com
4 Graduate of “Iuliu Hațieganu” Faculty of Medicine, University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania
5 Department of Neurology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania; vvacaras@umfcluj.ro
6 Department of Cardiology, “Niculae Stăncioiu” Heart Institute, 400001 Cluj-Napoca, Romania; dacianaelena.popa@gmail.com
7 “Prof. Dr. Ion Chirică” Oncology Institute, 400010 Cluj-Napoca, Romania; paulagparcalab@gmail.com
8 Department of Geriatrics-Gerontology, “Iuliu Hațieganu” University of Medicine and Pharmacy, 400139 Cluj-Napoca, Romania; valerdonca@gmail.com (V.I.D.); macarieantonia@yahoo.com (A.E.M.)
9 Department of Dermatology, Emergency County Hospital, 410032 Oradea, Romania; madalina.sava0508@gmail.com
* Correspondence: octavia.sabin@umfcluj.ro (O.S.); gsaraci@yahoo.com (G.S.); Tel.: +40-740-191-078 (O.S.)
† Authors with equal contribution.

Abstract: (1) Aim: The aim of this study was to assess the preferences of oral anticoagulants (OA) in patients diagnosed with deep vein thrombosis (DVT) of lower limbs or non-valvular atrial fibrillation (AF) requiring anticoagulation for medium/long term. (2) Materials and methods: the study included consecutive patients admitted with a diagnosis of either acute DVT of lower limbs (without signs of pulmonary embolism) or non-valvular AF who required oral anticoagulation, in a time frame of 18 months from January 2017 until June 2018. The following data were recorded: demographic variables, comorbidities (ischemic heart disease, arterial hypertension, heart failure, stroke, peripheral artery disease, diabetes mellitus, obesity), type and dose of OA (acenocoumarol, dabigatran, apixaban, rivaroxaban), complications due to the use of OA. (3) Results: AF patients were older and had considerably more cardiovascular comorbidities than DVT patients. Vitamin K antagonists (VKA) were more likely to be administered in patients with AF, as they had indication for indefinite anticoagulation. VKA were more frequently prescribed in patients with ischemic heart disease, heart failure, and diabetes compared with DVT patients. Moreover, complications related to OA use were more frequent in the VKA group. Almost half of patients with acute DVT (48.5%) were treated with direct OA (DOAC) rather than VKA, and only a quarter of AF patients (24.8%) were treated with DOACs.

Keywords: atrial fibrillation; deep vein thrombosis; anticoagulant choice; direct oral anticoagulants; vitamin K antagonists
1. Introduction

Hypercoagulable state is an important issue in modern medicine, relevant to every clinical specialty including visceral, obstetrical, and orthopedic surgery or medical branches like cardiology, pulmonology, gastroenterology, oncology, internal medicine, and recently described COVID-19. The main triad of clot formation was depicted more than 100 years ago by Rudolf Virchow and includes hypercoagulation, parietal lesion, and blood stasis, and these aspects are ubiquitous in every case of thrombus formation [1]. From that moment, a wide range of therapeutic approaches have been implemented to date, the most important one being the advent of the new oral anticoagulant era, more than ten years ago. From their first use in orthopedic surgery, especially in knee surgery, use of these drugs expanded across the field year after year in many other conditions like atrial fibrillation, deep vein thrombosis, and malignancies [2].

Atrial fibrillation (AF) is a clinical entity characterized by the loss of sinoatrial node control over atrial depolarization and contraction and its replacement with chaotic disorganized electric and mechanical activity of atria, with subsequently compromised pomp function and disturbances also in their conduct and reservoir functions [3]. Even with the availability of recently introduced procedures like radiofrequency ablation or left atrial appendage closure devices, anticoagulant therapy remains mandatory after these device procedures as thrombi can originate also in the left atrium [4]. The necessity of anticoagulation in AF is established by the CHA2DS2-VASc score and the hemorrhagic risk is estimated by HAS-BLED score [5]. As studies showed noninferiority of direct oral anticoagulants (DOAC) when compared to vitamin K antagonists (VKA) with the benefit of lower hemorrhagic events, choosing the oral anticoagulant (OA) involves evaluating the cost, the accessibility to monitoring INR (International Normalized Ratio), and the risk of having fluctuant INR due to patient characteristics or drug interactions [6].

Deep vein thrombosis (DVT) and pulmonary embolism are initiated by the formation of a thrombus in a deep vein followed by its virtual wedging into distant vessels, mainly branches of pulmonary arteries in the absence of communication between left and right heart. In the latter case, any location within the circulatory system is virtually possible [7]. While for AF, the use of anticoagulation is subject to debate according to previously mentioned scores, in the case of acute DVT, anticoagulant therapy is mandatory and must be continued for a medium or long period after the acute phase, and in certain conditions, its use is lifelong [7].

Choosing between VKA and DOAC for medium/long term is problematic, as acquiring the target INR could be difficult for some patients and is a reason for multiple ambulatory consultations. There is no consensus on this issue, so the physician must discuss and establish the adequate product for each patient. Besides cost, the only shortcoming of DOAC—until recently—was the lack of an antidote in the case of overdose or high serum levels of various causes; this obstacle was overcome with the introduction of Idarucizumab for dabigatran and Adexanet alpha for direct factor Xa inhibitors, thus making the choice even more complicated as the new antidotes are expensive [8].

The aim of this study was to assess the preferences of oral anticoagulant (OA) in patients diagnosed with DVT of lower limbs or non-valvular AF, who required anticoagulation for medium/long term.

2. Materials and Methods

The study was a retrospective, analytic, observational, transversal, cohort type. We included all consecutive patients admitted with a diagnosis of acute DVT of lower limbs without signs of pulmonary embolism or non-valvular AF, who required oral anticoagulation, in a time frame of 18 months from January 2017 until June 2018. The study was approved by the hospital’s ethics committee (no. 350/13 November 2014) and all patients gave informed consent. Patients diagnosed with cancer or autoimmune diseases were excluded from the study.

The following data were recorded: demographic variables, comorbidities (ischemic heart disease, arterial hypertension, heart failure, stroke, peripheral artery disease, diabetes mellitus, obesity),
type and dose of OA (acenocoumarol, dabigatran, apixaban, rivaroxaban), complications due to OA (upper or lower gastrointestinal bleeding, hematuria, epistaxis, ecchymosis, INR ≥ 4.5).

A statistical analysis was carried out using the MedCalc Statistical Software version 19.4.1 (MedCalc Software bv, Ostend, Belgium, 2020). The normality of distribution for the quantitative data was verified with the Shapiro–Wilk test. Quantitative variables were described using mean and standard deviation. Qualitative data were characterized by frequencies and percentages. Between-group comparisons were performed using the Student T test for quantitative variables and chi-square tests or Fisher’s exact test for qualitative variables. A multivariate analysis was employed to determine which variables were independently associated with OA preference. Variables that reached statistical significance in the univariate analysis were introduced in a logistic regression. A p value > 0.05 was considered statistically significant.

3. Results

Patients’ characteristics are summarized in Table 1. Most of the patients with AF had advanced age and presented statistically significant more cardiovascular comorbidities, as compared with patients with DVT.

| Variables                      | AF (n = 569) | DVT (n = 105) | p      |
|--------------------------------|-------------|--------------|--------|
| Age (years)                    | 74.6 ± 9.6  | 65.6 ± 14.7  | < 0.001|
| Gender                         |             |              | 0.4    |
| Female                         | 295 (51.8%) | 50 (47.6%)   |        |
| Male                           | 274 (48.2%) | 55 (52.4%)   |        |
| Ischemic heart disease         | 390 (68.5%) | 25 (23.8%)   | < 0.001|
| Arterial hypertension          | 477 (83.8%) | 70 (66.7%)   | < 0.001|
| Diabetes mellitus              | 149 (26.4%) | 16 (15.2%)   | 0.01   |
| Heart failure                  | 467 (82.1%) | 28 (26.7%)   | < 0.001|
| History of stroke              | 97 (17.1%)  | 4 (3.8%)     | < 0.001|
| Peripheral artery disease      | 36 (6.3%)   | 1 (1%)       | 0.04   |
| Obesity                        | 136 (23.9%) | 42 (40%)     | 0.5    |
| Chronic kidney disease         | 134 (23.6%) | 11 (10.5%)   | 0.004  |
| DOAC                           |             |              | <0.001 |
| Dabigatran                     | 35 (6.15%)  | 42 (40%)     |        |
| Rivaroxaban                    | 36 (6.3%)   | 8 (7.6%)     |        |
| Apixaban                       | 53 (9.3%)   | 1 (0.9%)     |        |
| Acenocoumarol                  | 445 (78.2%) | 54 (52.4%)   |        |

AF—atrial fibrillation; DVT—deep vein thrombosis; DOAC—direct oral anticoagulant.

There were several differences between patients treated with VKA and those receiving DOAC (Table 2). VKA were more frequently prescribed in patients with ischemic heart disease, heart failure, and diabetes. Complications related to OA use were more frequent in the VKA group (Figure 1).

A multivariate logistic regression was used to determine the independent association of several variables with OAC preference (Table 3). Patients with atrial fibrillation, ischemic heart disease, or diabetes mellitus had a higher probability of receiving VKA.

Dabigatran was administered to 77 patients; 41 (53.2%) of them received 150 mg p.o b.i.d. and 36 (46.7%) received 110 mg p.o b.i.d. Rivaroxaban was administered to 44 patients, from which seven (15.9%) received 15 mg p.o b.i.d., 20 (45.4%) received 20 mg p.o q.d., and 17 (38.6%) received 15 mg mg p.o q.d. Apixaban was administered to 54 patients, from which 41 (75.9%) received 2.5 mg p.o b.i.d., and 13 (24.1%) received 5 mg p.o b.i.d. Acenocoumarol was administered to 499 patients; 68 (13.6%) of the acenocoumarol treated patients received over 28 mg weekly, 277 (55.5%) received
between 7 and 28 mg weekly, and 154 (30.8%) received under 7 mg weekly. Frequencies of use for each class of anticoagulants are detailed in Figure 2a,b.

| Table 2. Comparison between VKA and DOAC group. |
|-----------------------------------------------|
| Variables | VKA (499) | DOAC (175) | p     |
| Condition requiring OAC | AF | 445 (89.2%) | 124 (70.9%) | <0.001 |
| | DVT | 54 (10.8%) | 51 (29.1%) | |
| Gender | Female | 260 (52.1%) | 85 (48.6%) | 0.4 |
| | Male | 239 (47.9%) | 90 (51.4%) | |
| Age (years) | 73.7 ± 10.1 | 71.6 ± 13.3 | 0.06 |
| Ischemic heart disease | 333 (66.7%) | 82 (44.9%) | <0.001 |
| Arterial hypertension | 408 (81.8%) | 139 (79.4%) | 0.5 |
| Diabetes mellitus | 137 (27.7%) | 28 (16%) | 0.003 |
| Heart failure | 381 (76.4%) | 114 (65.1%) | 0.005 |
| History of stroke | 68 (13.7%) | 33 (18.9%) | 0.1 |
| Peripheral artery disease | 30 (6%) | 7 (4%) | 0.4 |
| Obesity | 135 (27.1%) | 43 (24.6%) | 0.5 |
| Chronic kidney disease | 109 (21.8%) | 36 (20.6%) | 0.8 |
| All complications related to OAC | 55 (11%) | 8 (4.6%) | 0.01 |

Complications

| Complications | VKA | DOAC | p     |
|---------------|-----|------|-------|
| Upper GI bleeding | 22 (4.4%) | 5 (2.9%) | 0.09 |
| Hematuria | 12 (2.4%) | 2 (1.1%) | |
| Ecchymosis | 10 (2%) | - | |
| Epistaxis | 11 (2.2%) | 1 (0.6%) | |

VKA—vitamin K antagonists; DOAC—direct oral anticoagulant; AF—atrial fibrillation; DVT—deep vein thrombosis; OAC—oral anticoagulant.

Figure 1. Oral anticoagulant complications. OAC—oral anticoagulants; VKA—vitamin K antagonist; DOAC—direct oral anticoagulant; GI—gastro-intestinal.
Table 3. Multivariate logistic regression for OAC preference.

| Variables               | B    | p     | OR    | 95% CI for OR |
|-------------------------|------|-------|-------|--------------|
| Age                     | 0.002| 0.7   | 1.002 | 0.986–1.019  |
| Atrial fibrillation     | 0.968| <0.001| 2.633 | 1.564–4.433  |
| Ischemic heart disease  | 0.532| 0.008 | 1.702 | 1.149–2.521  |
| Diabetes mellitus       | 0.561| 0.01  | 1.753 | 1.104–2.782  |
| Heart failure           | −0.078| 0.7  | 0.925 | 0.581–1.472  |
| Constant                | 0.718| 0.235 | 2.049 |              |

B—regression coefficient; OR—odds ratio; CI—confidence interval.

Figure 2. Anticoagulant choice. DOAC—direct oral anticoagulant (a). DVP—deep vein thrombosis (b). AF—atrial fibrillation.

4. Discussion

In the last decade, DOACs have secured a leading place as anticoagulant treatment in several diseases. They are safer drugs, with an efficiency at least equal to VKA, which does not require strict therapeutic monitoring [5,7,9]. Initially indicated in venous thromboembolism (VTE) prevention,
Healthcare 2020, 8, 404 6 of 9

later in stroke prevention in AF, DAOCs have been shown to be effective in the treatment of acute DVT, replacing conventional therapy, heparins, and VKA in several patients [9,10]. From the beginning of their use, two major drawbacks were noticed: the much higher price and the lack of an antidote in case of overdose. Attempts to overcome these drawbacks consist in the gradual reduction of costs, the introduction of reimbursement of these drugs in the insurance systems, the approval of generic variants of some of these drugs (rivaroxaban), and reversal agents. The medical community has witnessed a continuously growing interest in the last few years in replacing “the old coumarins” to these new “easy-to-take” anticoagulants.

A gradual increase in the proportion of DOAC usage in AF treatment was recently documented all over the world [11–13]. DOACs are initiated more frequently than VKA in numerous countries [11,13,14], contributing to an increase in appropriate prescribing of anticoagulants in AF. Despite DOACs’ current large availability and the increasing adherence to anticoagulation guidelines, sub-optimal anticoagulation in AF [13,15] and inappropriate use at DOAC initiation still represent pertinent issues [16].

The shift from VKA to DOACs was also observed for acute DVT treatment, after several studies showed that they constitute an effective and safer alternative to conventional anticoagulation [17]. There are no head-to-head trials to date to compare DOACs, but meta-analysis research has reported that DOACs are equally effective in preventing strokes and systemic embolisms in AF [9] and acute DVT [10]. Apixaban treatment results in a significant reduction in major bleeding and clinically relevant bleeding compared to other DOACs [9,10]. Therefore, guidelines now prefer DOACs over conventional treatment for acute DVT treatment in patients without active cancer [7]. Current recommendations in acute DVT treatment do not discriminate between DOACs and indicate that dabigatran, endoxaban, and VKA treatment should be preceded by at least 5 days of low weight molecular heparins. As for apixaban and rivaroxaban, it is possible to begin an oral treatment with these DOACs from day 1. The aforementioned arguments may seem as a huge advantage in theory, but in real-life practice, the reluctance of some doctors with a lifelong experience with VKA treatment (“the classic way”) can be a significant obstacle in choosing DOACs.

In our study, AF patients were older and had considerably more cardiovascular comorbidities than DVT patients. VKA were more frequently prescribed in patients with ischemic heart disease, heart failure, and diabetes compared with DVT patients. Moreover, complications related to OA use were more frequent in the VKA group. Patients with comorbidities are more likely to be treated by VKA.

Almost half of patients with acute DVT (48.5%) were treated with DOACs rather than VKA, and only a quarter of AF patients (24.8%) were treated with DOACs. In other similar studies on hospitalized patients with AF, the proportion of DOAC use was higher, from 35% in another hospital in Romania [18] to more than 50% in Greece [19]. Compelling data prove that DOACs are now the preferred therapy for initiation of OA in patients with AF, including in patients at higher risk of stroke or bleeding [11,13]. VKA were more likely to be administered in patients with AF, as they had indication for indefinite anticoagulation. This might be considered a potential major problem if we only consider the risk of bleeding during treatment, which is higher in the case of AF due to the indefinite duration of treatment compared to DVT treatment. In our study, the preference for VKA was probably due to the cost involved: DOACs’ financial burden is sustainable for the patients for 3 to 6 months, but not for a long period. The fact that, at the time of the study (2018), DOACs were not reimbursed by the National Assurance argues for the disproportionate costs of the two OAs being a relevant factor influencing therapeutic decision.

Notably, we have reported a clear predilection for choosing dabigatran in acute DVT (more than 40% patients) over other DOACs. This was not the case for AF patients treated with DOACs, for whom the distribution between the three DOACs available seems equal, with small preference for apixaban (9.3% vs. 6.1% dabigatran and 6.3% rivaroxaban).

The preferences and the local standard practices for DOACs in acute DVT vary worldwide and are influenced by cost, differences in reimbursement, or accessibility of therapies [20]. In the GARFIELD-VTE study, a large multinational observational real-world treatment practice in acute venous
thromboembolism, overall, one half of the patients received a DOAC either alone or with transition from parenteral anticoagulant, with a larger proportion in Europe and North America (up to 60%). The most frequently prescribed was rivaroxaban and only a minority, around 5%, received dabigatran [20]. The choice of rivaroxaban was probably the result of it being the first DOAC recommended for the treatment of VTE and the early introduction of generic alternatives. Apixaban is preferred in some countries for AF and VTE [11,16]. Another possible influence over the therapeutic decision is the estimated duration of OA treatment. An estimate of one third [7] of the DVT patients will need a long-term anticoagulation plan, but, unfortunately, there are no follow-up studies for these patients on DOACs vs. VKA over a longer period than one year. Dabigatran was the first DOAC available in Romania and the high percentage of prescription in acute DVT may be explained by physicians’ confidence and experience with this drug [18] and by a slight difference in cost between DOACs in favor of dabigatran. Even if patients with AF have more comorbidities and their anticoagulant treatment is needed indefinitely—which translates into a higher risk of bleeding complications—the clinicians in our center continue to opt for VKA, probably because of economic reasons.

Among the limitations of the study are the lack of information about the socio-economic status of the patients and the lack of follow-up, which is important in the assessment of the rate of complications and in light of the fact that several patients will abandon the treatment with DOACs. A future direction of research would be to evaluate the dynamics in time of the choice of OA, how the costs of these drugs influence the prescription, and physicians’ reasons to choose a particular OA, beside guidelines and drug labeling.

5. Conclusions

Our study showed that VKA are the preferred OA for long-term stroke prevention in AF and DOACs are mostly used in patients with DVT—a pathology that requires a shorter period of anticoagulation. Complications related to OA use were more frequent in patients treated with VKA.

Author Contributions: Conceptualization, Š.C.V., S.I.V., S.C. and O.S.; methodology, Š.C.V., S.I.V., O.S. and S.C.; validation, V.V., S.C. and A.E.M.; formal analysis, Š.C.V. and O.S.; investigation, S.C., G.S., D.E.P., A.E.M., P.P., data curation, Š.C.V., M.S. and O.S.; writing—original draft preparation, Š.C.V., G.S. and O.S.; writing—review and editing, Š.C.V., S.I.V., S.C. and O.S.; visualization, M.S., V.I.D. and D.E.P.; supervision, A.D.B.; project administration, Š.C.V. and S.I.V. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wolberg, A.S.; Aleman, M.M.; Leiderman, K.; Machlus, K.R. Procoagulant Activity in Hemostasis and Thrombosis: Virchow’s Triad Revisited. Anesth. Analg. 2012, 114, 275–285. [CrossRef] [PubMed]
2. Tritschler, T.; Kraaijpoel, N.; Gal, G.L.; Wells, P.S. Venous Thromboembolism: Advances in Diagnosis and Treatment. JAMA 2018, 320, 1583–1594. [CrossRef] [PubMed]
3. Wijesurendra, R.S.; Casadei, B. Atrial Fibrillation: Effects beyond the Atrium? Cardiovasc. Res. 2015, 105, 238–247. [CrossRef]
4. Mangrolia, N.; Punjabi, P. The Cessation of Oral Anticoagulation Following Left Atrial Appendage Surgery. Future Cardiol. 2018, 14, 407–415. [CrossRef] [PubMed]
5. Kirchhof, P.; Benussi, S.; Kotecha, D.; Ahlsson, A.; Atar, D.; Casadei, B.; Castella, M.; Diener, H.C.; Heidbuchel, H.; Hendriks, J.; et al. ESC Scientific Document Group. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with EACTS. Eur. Heart J. 2016, 37, 2893–2962. [CrossRef] [PubMed]
6. Barco, S.; Granzieria, S.; Coppens, M.; Douxfils, J.; Nijkeuter, M.; Riva, N.; Vanassche, T.; Zhang, G.; Lin, M.; Kamphuisen, P.W.; et al. Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SMa-TT2-R2 Score: An Analysis of Hokusai-VTE. Thromb. Haemost. 2019, 119, 675–684. [CrossRef] [PubMed]
7. Konstantinides, S.V.; Meyer, G.; Becattini, C.; Bueno, H.; Geersing, G.J.; Harjola, V.P.; Huisman, M.V.; Humbert, M.; Jennings, C.S.; Jiménez, D.; et al. 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaboration with the European Respiratory Society (ERS) The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur. Heart J. 2020, 41, 543–603. [CrossRef] [PubMed]

8. Cuker, A.; Burnett, A.; Triller, D.; Crowther, M.; Ansell, J.; Van Cott, E.M.; Wirth, D.; Kaatz, S. Reversal of Direct Oral Anticoagulants: Guidance from the Anticoagulation Forum. Am. J. Hematol. 2019, 94, 697–709. [CrossRef] [PubMed]

9. Sterne, J.A.; Bodalia, P.N.; Bryden, P.A.; Davies, P.A.; López-López, J.A.; Okoli, G.N.; Thom, H.H.; Caldwell, D.M.; Dias, S.; Eaton, D.; et al. Oral Anticoagulants for Primary Prevention, Treatment and Secondary Prevention of Venous Thromboembolic Disease, and for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis and Cost-Effectiveness Analysis. Health Technol. Assess. Winch. Engl. 2017, 21, 1–386. [CrossRef] [PubMed]

10. Cohen, A.T.; Berger, S.E.; Milenković, D.; Hill, N.R.; Lister, S. Anticoagulant Analysis for Patients with VTE-Evidence from a Systematic Literature Review of Network Meta-Analyses. Pharmacol. Res. 2019, 143, 166–177. [CrossRef] [PubMed]

11. Maura, G.; Billionnet, C.; Drouin, J.; Weil, A.; Neumann, A.; Pariente, A. Oral Anticoagulation Therapy Use in Patients with Atrial Fibrillation after the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants: Findings from the French Healthcare Databases, 2011–2016. BMJ Open 2019, 9, e026645. [CrossRef] [PubMed]

12. Kennedy, C.; Ni Choitir, C.; Clarke, S.; Bennett, K.; Barry, M. Direct Oral Anticoagulants Uptake and an Oral Anticoagulation Paradox. Br. J. Clin. Pharmacol. 2020, 86, 392–397. [CrossRef] [PubMed]

13. Lowres, N.; Giskes, K.; Hespe, C.; Freedman, B. Reducing Stroke Risk in Atrial Fibrillation: Adherence to Guidelines Has Improved, but Patient Persistence with Anticoagulant Therapy Remains Suboptimal. Korean Circ. J. 2019, 49, 883–907. [CrossRef] [PubMed]

14. Wilke, T.; Bauer, S.; Mueller, S.; Kohlmann, T.; Bauersachs, R. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient-Patient-Cent. Outcomes Res. 2017, 10, 17–37. [CrossRef] [PubMed]

15. Vesa, Ş.C.; Vlaicu, S.I.; Sabin, O.; Văcăraş, V.; Cîrisan, S.; Istratoaie, S.; Samantar, F.; Popa, D.E.; Macarie, A.E.; Buzoianu, A.D. Evaluating Physician Adherence to Antithrombotic Recommendations in Patients with Atrial Fibrillation: A Pathway to Better Medical Education. Int. J. Environ. Res. Public. Health 2020, 17, 4008. [CrossRef] [PubMed]

16. Barben, J.; Menu, D.; Rosay, C.; Vovelle, J.; Mihai, A.M.; Nuss, V.; d’Athis, P.; Putot, A.; Manckoundia, P. The Prescription of Direct Oral Anticoagulants in the Elderly: An Observational Study of 19 798 Ambulatory Subjects. Int. J. Clin. Pract. 2017, 71, e13420. [CrossRef] [PubMed]

17. Robertson, L.; Kesteven, P.; McCaslin, J.E. Oral Direct Thrombin Inhibitors or Oral Factor Xa Inhibitors for the Treatment of Deep Vein Thrombosis. Cochrane Database Syst. Rev. 2015, 6. [CrossRef] [PubMed]

18. Tica, O.A.; Tica, O.; Antal, L.; Hatos, A.; Popescu, M.I.; Pantea-Śtoian, A.; Bratu, O.G.; Gáman, M.A.; Pițuru, S.M.; Diaconu, C.C. Modern oral anticoagulant treatment in patients with atrial fibrillation and heart failure: Insights from the clinical practice. Farmacia 2018, 66, 972–976. [CrossRef]

19. Kartas, A.; Samaras, A.; Vasdeki, D.; Dividis, G.; Fotos, G.; Paschou, E.; Forozidou, E.; Tsoukra, P.; Kotsi, E.; Goulas, I.; et al. Hospitalization Affects the Anticoagulation Patterns of Patients with Atrial Fibrillation. J. Thromb. Thrombolysis 2019, 48, 225–232. [CrossRef] [PubMed]

20. Haas, S.; Ageno, W.; Weitz, J.J.; Goldhaber, S.Z.; Turpie, A.G.G.; Goto, S.; Angchaisuksiri, P.; Nielsen, J.D.; Kayani, G.; Zaghdoun, A.; et al. Anticoagulation Therapy Patterns for Acute Treatment of Venous Thromboembolism in GARFIELD-VTE Patients. J. Thromb. Haemost. 2019, 17, 1694–1706. [CrossRef] [PubMed]

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).